In the secondary analysis, the significantly less conservative but clinically meaningful criterion of stable reaction (outlined as being a fifty% or more reduction in MADRS from baseline for two weeks) was used. Of the patients who achieved steady response, 25.8% inside the esketamine group and fifty seven.six% inside the placebo https://joleney937wcg7.hazeronwiki.com/user